Goldshield is a profitable, marketing-led, emerging pharmaceutical and healthcare company. Our operations in the United States of America are located in West Palm Beach, Florida. Growth has been rapid and achieved both organically and through astute product acquisition.
The Directors believe that this growth has been driven principally by the Group’s marketing skills, customer focus, product ranges and developments, financial controls and extensive staff training. Goldshield aims to service a much broader segment of the pharmaceutical and healthcare markets than many similarly sized pharmaceutical companies.
The company sells ethical (prescription) pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements and a wide range of other healthcare products. To service its customer’s needs from the highly regulated to the consumer driven markets, Goldshield operates as two divisions, the Pharmaceutical Division and the Healthcare Division.
Goldshield chooses to market products which match its rigorous marketing and financial return criteria. Product licenses and brands, where appropriate, are acquired or, increasingly, developed internally. The Directors consider new opportunities to acquire further products and develop product line extensions and new chemical entities which meet the Group’s investment criteria.
The Group was founded by the Company’s Chairman, Ajit Patel, together with its Chief Operating Officer, Kirti Patel, and Shane Gogerly, Director of Sales of Pharmaceutical Products. Goldshield commenced trading in 1991 with a range of pharmaceutical and healthcare products.
The first pharmaceutical product was acquired from Glaxo in 1992 and there have been subsequent product acquisitions from SmithKline Beecham, Medeva, Warner Lambert and American Home Products.
Between 1991 and 1993, the Group raised equity finance of $1.84 from individual investors, many of whom are doctors, pharmacists, or from within the pharmaceutical industry. The Group became profitable in the year ended 31 March 1993.
During 1993, the Group started to sell Healthcare products direct to consumers through mail order, and started the development of its own pharmaceutical products in 1995. It received its first UK marketing authorization for a pharmaceutical product licensed to and developed by the Group in 1996.
In 1997, the Healthcare Division’s distribution and call center and the Group’s product development laboratory at Thornton Heath were opened.
In June 1998, the Group went public on the London Stock exchange.
Goldshield aims to continue to grow organically, through acquisition and through the formation of strategic alliances. The Group is currently investing heavily in the research and development of new pharmaceutical products. Thus the next few years will see a stream of new Goldshield products coming onto the market. Demand from consumers for quality natural Healthcare products has grown dramatically over the past few years and the indications are that this demand will continue to accelerate in the future. In order to meet this demand, the Healthcare Division is constantly developing new products and creating new distribution channels, which include retail outlets and the Internet. Continued expansion into international markets represents an important plank of the Group’s long-term strategy and increased investment in the export side of the business is planned. Goldshield’s phenomenal growth since its foundation has been built upon sound commercial and marketing principles. We intend to continue this success in the new century, by remaining true to these fundamental principles and diversifying where appropriate.